TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03814967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
Study: NCT02564900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a (DP1)
Description: DS-8201a to be administered via intravenous (IV) dose. DS-8201a (DP1) was used for the Dose Escalation phase and for Dose expansion Parts 2a, 2b, 2c, and 2d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a (DP1)
Description: DS-8201a to be administered via intravenous (IV) dose. DS-8201a (DP1) was used for the Dose Escalation phase and for Dose expansion Parts 2a, 2b, 2c, and 2d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a (DP2)
Description: DS-8201a is to be administered via intravenous (IV) dose. DS-8201a (DP2) was used only used for Dose Expansion Part 2e.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a (DP)
Description: DS-8201a (DP) is to be administered via intravenous (IV) dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a (DP)
Description: DS-8201a (DP) is to be administered via intravenous (IV) dose.
Study: NCT01146093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin Sodium
Description: Pravastatin Sodium Tablets 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin Sodium
Description: Pravastatin Sodium Tablets 80 mg
Study: NCT03003494

Intervention type: DRUG
Intervention: Spiolto® Respimat®
Description: observations taken in a period of approximately 6 weeks
Study: NCT00185263

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AdF5FGF-4 vs. Placebo
Description: Intracoronary infusion

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AdF5FGF-4 vs. Placebo
Description: Intracoronary infusion
Study: NCT00754338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcon Opti-Free® RepleniSH®
Description: Marketed Multipurpose Disinfecting Care System
Study: NCT01854788

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autogenic drainage
Description: It was performed following J. Chevallier recommendations.In this trial it was considered a self-administrated technique because physiotherapist only gave oral advice in order to ensure a correct performance of the technique.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Slow expiration with glottis opened in lateral posture
Description: It was performed following Postiaux´s recommendations. In this trial the technique was considered active-assisted because the physiotherapy played a role important in their execution.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Temporary-positive expiratory pressure
Description: The diaphragmatic breathing was required for this technique whereas patients remain seated in front of the device with a nose clip. The inspiratory /expiratory ratio was 1:2.It was taken into account as a device-administrated technique for this trial.
Study: NCT01299038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin
Description: Taken orally once a day for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin
Description: Taken orally once a day for 4 weeks
Study: NCT00754338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcon Opti-Free® RepleniSH®
Description: Marketed Multipurpose Disinfecting Care System

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B&L ReNu MultiPlus™
Description: Marketed Multipurpose Disinfecting Care Systems

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B&L ReNu MultiPlus™
Description: Marketed Multipurpose Disinfecting Care Systems
Study: NCT00185263

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: AdF5FGF-4 vs. Placebo
Description: Intracoronary infusion
Study: NCT02551471

Intervention type: OTHER
Intervention: MDT (Multidisciplinary team) meeting observation
Description: 3 per centre with real patient cases and theoretical patient cases (blinded pelvic MRI re-reading).

Intervention type: OTHER
Intervention: Semi-structured exploratory interviews and focus group with MDT health professional attendees
Description: Will identify care management systems for PRC-bTME and LRRC patients, explore social representations that direct the formulation of a therapeutic decisions and identify cultural, medical and personal factors

Intervention type: OTHER
Intervention: Semi-structured exploratory interviews and focus group with MDT health professional attendees
Description: Will identify care management systems for PRC-bTME and LRRC patients, explore social representations that direct the formulation of a therapeutic decisions and identify cultural, medical and personal factors
Study: NCT00005807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-247550
Description: anticancer agent for the treatment of patients with malignant tumors.
Study: NCT02752061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Potlako intervention
Description: Multicomponent intervention including:~* provider training on early detection and diagnostic approaches to cancer~* patient education on importance of obtaining timely cancer diagnosis~* provision of a patient navigator to facilitate diagnosis and entry into care~* provision of transportation support to vulnerable patients
Study: NCT01748500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Study: NCT02889939

Intervention type: OTHER
Group type: OTHER
Intervention: UC + ETT
Description: UC: A 3-week UC period, where the participants were not offered any new rehabilitation activities but were allowed to continue their regular treatment for a maximum of 3 hours per week.~ETT: The rehabilitation facilities were located in a climate that allowed and encouraged both indoor and outdoor activities. The ETT was individually tailored. Participants exercised in the same room/place as the other participants in groups of 4-9. Physical exercise was scheduled 3.5-6 hours per day, 5½ days per week for 3 weeks. The training was characterized by repetitive mass practice of gradually increasing difficulty and noncompensatory strategies, such as enforcing use of the affected side.~Beyond scheduled activities, participants were encouraged to physically engage themselves in a challenging outdoor environment.
Study: NCT03829254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-7738
Description: NUC-7738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-7738
Description: NUC-7738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab
Study: NCT03382834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 20 mg orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 400 mg orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorinostat
Description: 400 mg orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral drugs
Description: Participants will receive antiretroviral drugs provided by their own doctors. Antiretroviral drugs will not be provided by the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral drugs
Description: Participants will receive antiretroviral drugs provided by their own doctors. Antiretroviral drugs will not be provided by the study.
Study: NCT03475862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTI-821 capsule Manipulated
Description: PTI-821 (oxycodone) 40 mg extended release capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTI-821 Non-manipulated
Description: PTI-821 (oxycodone) 40 mg capsule extended release capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyContin
Description: Crushed OxyContin (oxycodone) extended-release 40 mg tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebos for PTI-821 and oxycodone IR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Crushed oxycodone 40 mg immediate release tablet
Study: NCT01320007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preset increase in frusemide dose
Description: All patients in Group 1 will have the Optivol function and alerts switched on. Optivol levels will be downloaded monthly via the Medtronic Carelink Network (for those patients who have it) or during pacemaker follow up appointments.~If the Optivol alarm goes off, all patients will be requested to contact a member of the research team by phone and those with rising Optivol (irrespective of the presence or absence of heart failure symptoms) will be requested to increase the dose of diuretic that they are on by 50% for 1 week then revert to their usual dose after 7 days. A routine renal function check will be performed at the end of the week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: The Optivol data for these patients will be downloaded periodically (at each scheduled device check) and recorded but will not be available at follow up in the heart failure clinic.. These patients will act as controls for group 1 patients. They will undergo baseline investigations and then will undergo routine heart failure treatment and follow-up in the heart failure clinic. These will include a routine clinical evaluation, body weight and blood analysis as per the heart failure clinic protocol. Medications will be reviewed and changed according to clinical needs.
Study: NCT03546517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Dry Needling
Description: Sham Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
Study: NCT03647306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Total Caloric Intake
Description: Provide subjects a regimented amount of calories at each meal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late Total Caloric Intake
Description: Provide subjects a regimented amount of calories at each meal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Extended Overnight Fast
Description: Provide subjects a regimented amount of calories at each meal.
Study: NCT01851148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteopathic manipulative treatment
Description: It consists of 8 sessions in 6 months. Each osteopathic session is based on a structural evaluation and an indirect technique treatment.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham treatment
Description: Sham therapy was administered with subjects lying supine on the treatment table while the operator used light manual contact to treat the subject. The practitioner's attention was distracted by subtracting serial seven calculation in silence
Study: NCT03199170

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intrathecal morphine
Description: 0.5% Hyperbaric bupivacaine 2 ml add morphine 0.2 mg for spinal anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilateral Quadratus Lumborum Block
Description: 0.25% Bupivacaine 25 ml each side for quadratus lumborum block without spinal morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine with bilateral Quadratus Lumborum Block
Description: 0.5% Hyperbaric bupivacaine 2 ml add morphine 0.2 mg for spinal anesthesia and 0.25% Bupivacaine 25 ml each side for quadratus lumborum block
Study: NCT02945462

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous mesenchymal stem cells
Description: Patients will be injected with autologous mesenchymal stem cells, intracavernously
Study: NCT05118321

Intervention type: DEVICE
Group type: OTHER
Intervention: Custom-made upper limb exosuit and hand exoskeleton
Description: Participants go through 3 90-min sessions in a clinic setting and perform a series of functional tasks adapted from motor activity log and bilateral upper limb tasks with and without the device.
Study: NCT04611659

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing and Educational Training (MIET)
Description: Women in the intervention arm will receive a motivational interviewing intervention coupled with education on contraception and the potential for neonatal abstinence syndrome.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing and Educational Training (MIET)
Description: Women in the intervention arm will receive a motivational interviewing intervention coupled with education on contraception and the potential for neonatal abstinence syndrome.
Study: NCT03691207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL101
Description: AL101 is a small-molecule that inhibits gamma secretase, an enzyme which plays a key role in the activation of the Notch signaling pathway by releasing the Notch intracellular domain (NICD) of all four Notch receptors from the membrane.~In patients with aberrant Notch signaling, AL101 may inhibit Notch signaling and potentially impede tumor growth.The drug is administered intravenously
Study: NCT04520997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Defyne
Description: Up to 2 milliliters (ml) of Restylane Defyne per treatment site (chin and surrounding area) with maximum of total 4 ml at baseline, up to 2 ml of Restylane Defyne per NLF and ML at week 3 and optional up to 2 ml of Restylane Defyne per facial half for NLF and ML in combination with a total of 2 ml in the chin and surrounding area at week 6.
Study: NCT04402749

Intervention type: OTHER
Intervention: Nephrectomy
Description: Patients underwent nephrectomy
Study: NCT03013933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil Hydrochloride
Description: Given PO
Study: NCT00909077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone tablets: 40 mg/day for four days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone and Rituximab
Description: Dexamethasone tablets: 40 mgs/day for four days Rituximab iv 375 mg/m\^2 weekly, a total of four times. Administered on day 2 (i.e. the patient has been treated with Dexamethasone for one day)
Study: NCT00648856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline Hydrochloride Tablets 100 mg
Description: 100mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoloft® Tablets 100 mg
Description: 100mg, single dose fed
Study: NCT00929357

Intervention type: DRUG
Intervention: DMARDs or Biologics

Intervention type: DRUG
Intervention: DMARDs or Biologics
Study: NCT01720628

Intervention type: OTHER
Intervention: serum levels of angiogenin, bFGF, VEGF
Description: Behçet's patients
Study: NCT01851148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptans
Description: administration of triptans drug treatment according to international guidelines

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: triptans
Description: administration of triptans drug treatment according to international guidelines

Intervention type: DRUG
Group type: OTHER
Intervention: triptans
Description: administration of triptans drug treatment according to international guidelines
Study: NCT00892827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab (Mabthera) , FFP (Fresh Frozen Plasma)
Description: Rituximab (375 mg/m2) with FFP will be given every two weeks
Study: NCT01159327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400mg, bid(800mg/day), daily, PO
Study: NCT01460927

Intervention type: DEVICE
Group type: OTHER
Intervention: TriActive+ RF
Description: Radio frequency handpiece uses a multi-polar technology with a particular electrical frequency of 1MHz. The handpiece has a special skin contact identification system which delivers energy only when electrodes are adherent to the skin surface in order to avoid the prickling sensation when the treatment starts.
Study: NCT02495610

Intervention type: OTHER
Group type: OTHER
Intervention: Gait analysis and MRI:
Description: * Gait analysis: Treadmill with pressure sensors (FDM-THM-M-System; 'Zebris' medical GmbH), study-specific, but routine procedures.~* MRI: Performed in a scanner at the University Hospital with standard MRI compatibility procedures; study specific is only the additional MRI after the CSF release with spinal tap or drainage.
Study: NCT06539364

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life surveys were conducted
Description: Quality of life surveys were conducted with OHIP-14, OHRQoL-UK and VAS

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quality of life surveys were conducted
Description: Quality of life surveys were conducted with OHIP-14, OHRQoL-UK and VAS
Study: NCT01165684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Insulin aspart added stepwise according to the largest meal following an evaluation of HbA1c.~Doses individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Insulin aspart added before each main meal. Doses individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Insulin detemir as basal insulin, adminstered once daily. Doses individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Insulin detemir as basal insulin, adminstered once daily. Doses individually adjusted.
Study: NCT00654706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertindole
Description: Once daily oral dose. Day 1-20: 4-16 mg/day (titration period). Day 21-84: 12, 16 or 20 mg/day (flexible treatment period).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Twice daily oral dose. Day 1-20: 50-500 mg/day (titration period). Day 21-84: 400, 500 or 600 mg/day (flexible treatment period).
Study: NCT01100593

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: length of IV catheter
Description: Subjects will be randomized to one of two IV catheter lengths

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: length of IV catheter
Description: Subjects will be randomized to one of two IV catheter lengths
Study: NCT04520997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Defyne
Description: Up to 2 ml of Restylane Defyne per NLF and ML at baseline, up to 2 ml of Restylane Defyne per treatment site (chin and surrounding area) with maximum of total 4 ml at week 3 and optional touch-up of up to 2 ml per facial half for NLF and ML in combination with a total of 2 ml in the chin and surrounding area at week 6.
Study: NCT01839084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: general anaesthesia with xenon 60% in oxygen (FiO2=0.4)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: general anesthesia with isoflurane 1.2% in 40% oxygen/medical air
Study: NCT00330421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO
Study: NCT03829826

Intervention type: BIOLOGICAL
Intervention: HyQvia
Description: Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase

Intervention type: BIOLOGICAL
Intervention: HyQvia
Description: Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
Study: NCT01718327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: sunitinib dose :37.5mg/day
Study: NCT03098134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Therapy
Description: Virtual Reality and Video based Exposure Therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Video based health education covering common myths and false believes about dental surgeries